Research programme: bispecific antibodies - Alligator Bioscience/Aptevo Therapeutics

Drug Profile

Research programme: bispecific antibodies - Alligator Bioscience/Aptevo Therapeutics

Alternative Names: ADC 1016; ALG.APV 527; ATOR 1016

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alligator Bioscience; Aptevo Therapeutics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD137 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Jul 2017 Preclinical development is ongoing in USA
  • 20 Jul 2017 Alligator Bioscience enters into a co-development agreement with Aptevo Therapeutics for development of ALG.APV 527 for solid tumours
  • 21 Jan 2014 Preclinical trials in Cancer in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top